Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243080 | 1.00 | HTR2C (0.58) | HTR2C | |
| SCHEMBL2545146 | 0.80 | HTR3E (0.56) | — | |
| Hydrochloric Acid SCHEMBL6298012 | 0.80 | HTR2C (0.55) | HTR2C | |
| Hydrochloric Acid SCHEMBL6305317 | 0.80 | HTR2C (0.55) | HTR2C | |
| Hydrochloric Acid SCHEMBL10523385 | 0.79 | KDM4E (0.57) | — | |
| SCHEMBL29301889 | 0.78 | HTR2C (0.70) | HTR2C | |
| SCHEMBL3683893 | 0.78 | HTR2C (0.47) | HTR2C | |
| SCHEMBL4244446 | 0.78 | HTR6 (0.61) | HTR2C | |
| SCHEMBL4244450 | 0.78 | HTR6 (0.61) | HTR2C | |
| SCHEMBL4247868 | 0.78 | HTR6 (0.61) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740591-B1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| CN-101087610-A | Arylpiperazine derivatives and their use as 5-HT1AUse of receptor ligands | SCHWARZ PHARMA S L (ES) | 2007-12-12 | — | — | CN | disclosed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.